Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

NCT01163227 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia Disorders

Interventions

DRUG: Placebo (single and multiple doses)
DRUG: AQW051 2 mg (single and multiple doses)
DRUG: AQW051 15mg (single and multiple doses)
DRUG: AQW051 100mg (single dose), and 50mg (multiple doses)

Sponsor

Novartis Pharmaceuticals